Closed-system suites, viral vector trains and chain-of-identity proven before first patient batch
Commissioning, qualification and validation software for cell and gene therapy where closed processing suites, viral vector production trains and cryopreservation systems all have to be qualified before the first patient-specific batch.
A cell and gene therapy (CGT) facility is built around small, flexible, often single-patient batches, closed and functionally-closed processing systems, viral vector production suites and cryopreservation chains where chain-of-identity and chain-of-custody are as critical as the equipment qualification itself. Deskely holds every closed system, vector production skid and cryogenic asset in one register with IQ, OQ, PQ and chain-of-identity evidence gates built in.
- Assets
- Closed processing suites, vector trains, cryo systems
- Test
- IQ, OQ, PQ, integrity testing, cryo mapping
- Traceability
- Chain of identity, chain of custody per batch
- Gate
- First patient-specific batch
Choose your project type
The problem
A single-patient batch cannot tolerate ambiguity, and a spreadsheet cannot prove which closed system processed which donor's cells.
A CGT facility runs closed or functionally-closed cell processing systems, viral vector production skids and cryopreservation and storage systems, often on a suite-by-suite basis where a single facility might support several different closed platforms at once.
When integrity testing records, viral vector qualification data and cryogenic mapping studies sit in separate vendor and lab notebooks, nobody can confirm before a first patient batch whether every closed system and cold chain link is qualified and every chain-of-identity control is proven.
Deskely tags every closed system, vector skid and cryo unit individually, with chain-of-identity fields built into the record set, so readiness for a first patient batch is verified system by system rather than assumed.
Setting up the register
Closed systems, vector skids and cryo units are tagged assets carrying their own integrity and chain-of-identity requirements.
Facility layout drawings, closed system process flow diagrams and equipment lists are parsed into a reviewed register, so every processing platform, vector production skid and cryopreservation unit carries its URS, its integrity test method and its vendor data from day one.
IQ, OQ and PQ protocols are templated once per closed system platform and instantiated across every suite that uses it, while chain-of-identity fields — donor or patient identifier linkage, suite occupancy logs and material segregation checks — are held as their own record type against each batch.
Cryogenic storage and transport systems, including mapping studies for temperature uniformity and alarm response verification, sit in the same register as the processing equipment, so cold chain readiness is derived from the same evidence set.
Execution
Integrity testing, cryo mapping and closed system qualification are proven system by system before a suite is released for patient material.
Closed system integrity is verified through pressure decay and connector integrity testing, captured against the specific platform, while viral vector production skids undergo qualification against titre, purity and potency-relevant process parameters.
Cryogenic storage and shipping systems are temperature-mapped across their full load configuration, with alarm response times verified and logged against the specific freezer, dewar or shipper tag rather than a generic cold chain summary.
Suite occupancy, gowning and material segregation controls that support chain of identity are logged per batch, so a cross-contamination risk finding is traceable to the specific suite, session and operator involved.
Release to first patient batch and ongoing manufacturing
The first patient batch runs on qualified systems and proven chain of identity, not a facility readiness memo written the week before the batch is scheduled.
First batch readiness draws on the qualification status of every closed system, vector skid and cryo unit plus chain-of-identity controls, so the evidence a quality unit needs before releasing a suite for patient material is an export rather than a last-minute compilation.
The handover pack for manufacturing and quality includes as-built process flow diagrams, integrity test methods and cryo mapping data keyed to the suite, giving the operating team the same record used to qualify it.
Every signature, donor or patient identifier link and suite occupancy record carries a name, role and timestamp, which is what a quality unit and a regulator reviewing an ATMP dossier expect before a facility is declared fit for patient-specific manufacturing.
Suite turnaround between patient batches
The same suite processes a different patient's cells the next day, and the turnaround between them is where a chain-of-identity failure actually happens.
A CGT facility rarely has one suite per patient; it has a small number of closed-system suites that turn over between patients, sometimes within the same week. The equipment qualification does not change between batches, but the cleaning, material clearance and occupancy reset absolutely has to.
When suite clearance is recorded as a checklist filed separately from the batch record, an auditor asking whether Suite 3 was fully cleared of Patient A's material before Patient B's cells entered is asking a question that requires reconciling two documents that were never designed to be read together.
Deskely ties suite clearance, material segregation checks and occupancy logs to both the outgoing and incoming batch records for that suite, so a turnaround is a single traceable event: what left, what was cleared, what was verified empty, and what came in next, all against the same suite tag.
The ATMP dossier
The record set a cell and gene therapy suite needs when every batch is patient-specific.
Advanced therapy manufacture has no room for batch-to-batch averaging: viral vector suites, closed-system bioreactors and cryopreservation stores each carry patient-linked risk. The dossier ties segregation, closed-processing and chain-of-identity controls to the qualification evidence a QP needs before a single-patient lot is released.
Closed-system bioreactor and cell processing skid IQ/OQ/PQ
Culture conditions and functionally closed transfers hold integrity across the manufacturing cycle.
Before first patient-linked campaign.
Cryopreservation and vapour-phase nitrogen store mapping reports
Storage temperature stays within the range required to preserve cell or vector viability.
Qualification and continuous monitoring thereafter.
Segregated suite airflow and pressure cascade verification
Cross-contamination between concurrent patient batches is prevented by directional airflow.
Commissioning and requalification of the suite.
Chain-of-identity and chain-of-custody traceability matrix entries
Every sample and product unit is unambiguously linked to its donor or patient throughout processing.
Continuous, from receipt to release.
Viral vector containment and inactivation validation reports
Vector shedding is contained and inactivated in effluent to the levels defined by risk assessment.
Before vector-handling operations commence.
Electronic batch record audit trail review
Manufacturing steps for a single-patient lot are attributable and cannot be altered without trace.
System qualification and each software release.
How it runs
From closed system FAT to first patient batch.
CGT programmes reward a register that treats chain of identity as a first-class record type, because a mixed-up donor identifier is the single failure mode a facility cannot recover from.
- 01
Model suites by closed system platform
Processing platforms, vector skids and cryo units modelled as assets tied to the suite they occupy.
- 02
Parse process flows and layouts
Closed system process flow diagrams and facility layouts drafted into a reviewed register with vendor data attached.
- 03
Template IQ/OQ/PQ and chain-of-identity fields
Protocols and identity controls defined once per platform, instantiated across every suite and batch.
- 04
Gate the first patient batch on full traceability
Batch readiness reported from qualified systems and chain-of-identity evidence, with findings tracked to closure.
FAQ
Questions about Cell and gene therapy scopes.
Keep reading
Life sciences and pharma commissioning
The full sector view: CQV strategy, the validation master plan and the terminology behind them.
Read moreMaster data
Equipment lists, URS-to-DQ traceability and vendor data sheets held as one structured source instead of scattered CQV binders.
Read moreITR records
IQ, OQ and PQ protocols defined once per equipment type and executed against every vessel, skid and room with a full audit trail.
Read moreOther life sciences project types: Sterile fill-finish CQV, Biologics drug substance CQV, Oral solid dose manufacturing CQV, API and chemical synthesis facility CQV, Vaccine manufacturing facility CQV, Cleanroom and HVAC qualification, Clean utilities qualification — WFI, clean steam and process gases, Lab and R&D facility CQV, Cold chain and warehouse qualification.
